FDA expands use of Xalkori
On March 11, the Food and Drug Administration (FDA) approved Xalkori (crizotinib) to treat people with metastatic non-small cell lung cancer (NSCLC) whose tumors…




*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.